Cargando…

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Geeta Geeta, Mota, Ines, Mologni, Luca, Patrucco, Enrico, Gambacorti-Passerini, Carlo, Chiarle, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876637/ https://www.ncbi.nlm.nih.gov/pubmed/29495603 http://dx.doi.org/10.3390/cancers10030062

Ejemplares similares

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Where astroparticle physics goes?
por: Jones, L W
Publicado: (2005)

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
por: Villa, Matteo, et al.
Publicado: (2021)

Brookhaven: Finding where the proton goes
Publicado: (1975)

Sexuality in midlife: Where the passion goes?
por: Magon, Navneet, et al.
Publicado: (2012)

Plant–Fungi Interactions: Where It Goes?
por: Priyashantha, A. K. Hasith, et al.
Publicado: (2023)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Dermatology: Where are We Coming from and Where are We Going to?
por: van de Kerkhof, Peter C. M.
Publicado: (2014)

Where is that smell coming from?
por: Brudner, Samuel, et al.
Publicado: (2022)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Where Do Phosphosites Come from and Where Do They Go after Gene Duplication?
por: Diss, Guillaume, et al.
Publicado: (2012)

Librarians as managers: an exploratory survey, where the time goes
por: Thomas, P A, et al.
Publicado: (1973)

Where are we coming from? What are we? Where are we going?
por: Ellis, John R.
Publicado: (1995)

Liquid biopsy: Where did it come from, what is it, and where is it going?
por: Morgan, Todd M.
Publicado: (2019)

13 Ebola virus: where does it come from and where is it going?
por: Murphy, Frederick A., et al.
Publicado: (1998)

Where new neurons come from
por: Lai, Eric C.
Publicado: (2003)

Where Do Introns Come From?
por: Catania, Francesco, et al.
Publicado: (2008)

Emigrants: Whence They Come and Where They Go
Publicado: (1894)

Where Do Our Patients Come In?
por: Dickason, H. F
Publicado: (1913)

Up or down: where comes Omicron?
por: Liu, Zezhong, et al.
Publicado: (2022)

Where Some Nuts Come from
Publicado: (1890)

When it starts in the skin and goes to the lungs, where does it stop?
por: Catarino Ferro, Ana Rita, et al.
Publicado: (2022)

Bacterial EPIYA effectors – Where do they come from? What are they? Where are they going?
por: Hayashi, Takeru, et al.
Publicado: (2013)

Cardiovascular Tissue Engineering: Where We Come From and Where Are We Now?
por: Smit, Francis E., et al.
Publicado: (2015)

Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
por: Daniels, Derek, et al.
Publicado: (2019)

Managing sarcoma: where have we come from and where are we going?
por: Bleloch, Jenna S., et al.
Publicado: (2017)

Ion-Powered Rotary Motors: Where Did They Come from and Where They Are Going?
por: Nandel, Vibhuti, et al.
Publicado: (2023)

We shall overcome (drug resistance) some day
por: Sharma, Geeta G., et al.
Publicado: (2019)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'
por: Ingle, James N
Publicado: (2008)

Partnership working in England—where we are now and where we’ve come from
por: Glasby, Jon, et al.
Publicado: (2011)

Communication skills in medicine: where do we come from and where are we going?
por: Ferreira-Padilla, Guillermo, et al.
Publicado: (2015)

Nanoparticles in the environment: where do we come from, where do we go to?
por: Bundschuh, Mirco, et al.
Publicado: (2018)

Gene Drive for Mosquito Control: Where Did It Come from and Where Are We Headed?
por: Macias, Vanessa M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_640ktbr3ebqucqrcvhvf5stv3f